New York, NY -- (SBWIRE) -- 01/10/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Corinthian Colleges Inc (NASDAQ:COCO), Zhone Technologies Inc (NASDAQ:ZHNE), DARA Biosciences Inc (NASDAQ:DARA), Gafisa SA (ADR) (NYSE:GFA)
Corinthian Colleges Inc (NASDAQ:COCO) showed a volume of 1.52 million shares by the end of last trade whereas the average volume of the stock remained 1.52 million shares. The stock opened the session at $1.70 but then moved to $1.72. At that price, the stock showed a positive performance of 1.18%. Corinthian Colleges, Inc. is a post-secondary education company in the United States and Canada. As of June 30, 2013, the Company had a student enrollment of 81,284 and operated 97 schools in 25 states, and 14 schools in the province of Ontario, Canada. It offers a variety of diploma programs and associate, bachelor's and master's degrees. The Company’s training program areas include healthcare, criminal justice, business, mechanical, trades, and information technology.
Will COCO Continue To Move Higher? Find Out Here
Zhone Technologies Inc (NASDAQ:ZHNE) opened the session at $6.47 and closed the session at $5.90. The stock showed a negative performance of -4.53% in previous trading session. Traded with volume of 1.48 million shares in the prior session and the average volume of the stock remained 16 741,357.00 shares. Zhone Technologies Inc. (Zhone) designs, develops and manufactures communications networks equipment for telecommunications, wireless and cable operators worldwide. With the Company's products and solutions, network service providers can migrate from traditional circuit-based networks to packet-based networks and from copper-based access lines to fiber-based access lines without abandoning the investments they have made in their existing infrastructures. In addition to its established product offerings,
Has ZHNE Found The Bottom And Ready To Gain Momentum? Find Out Here
DARA Biosciences Inc (NASDAQ:DARA) opened the session at $0.56 and closed the session at $0.580. The stock showed a positive performance of 1.17% in previous trading session. Traded with volume of 1.47million shares in the prior session and the average volume of the stock remained 1.04 million shares. The beta of the stock remained 1.50. DARA BioSciences, Inc. is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products. The Company has the exclusive United States marketing rights to its Soltamox (oral liquid tamoxifen). As of December 31, 2011, the Company continues to have an internal clinical development program for its two drug candidates, which cleared investigational new drug applications from the Food and Drug Administration (FDA), KRN5500 and DB959.
Why Should Investors Buy DARA After The Recent Gain? Just Go Here and Find Out
Gafisa SA (ADR) (NYSE:GFA) the stock decreased -3.34% and finished the session at $2.89. Traded with volume of 1.44 million shares in the prior session and the average volume of the stock remained 1.56 million shares. The beta of the stock remained 2.56. Gafisa SA is a Brazil-based company engaged in the homebuilding and real estate operations. The Company is involved in the promotion, administration, purchase, sale and trade of real estate properties; provision of financing services to real estate customers; construction and provision of civil engineering services, and development and implementation of marketing strategies related to its own or third party real estate projects. The Company divides its business into three segments: Gafisa,
Will GFA Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)